Browsing by Author "Sepulveda P."

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Novel molecular insights and public omics data in pulmonary hypertension
    (Elsevier B.V., 2021) Lopez-Crisosto C.; Arias-Carrasco R.; Maracaja-Coutinho V.; Lavandero S.; Lopez-Crisosto C.; Sepulveda P.; Verdejo H.E.; Castro P.F.; Sepulveda P.; Verdejo H.E.; Castro P.F.; Garrido-Olivares L.; Lavandero S.
    © 2021 Elsevier B.V.Pulmonary hypertension is a rare disease with high morbidity and mortality which mainly affects women of reproductive age. Despite recent advances in understanding the pathogenesis of pulmonary hypertension, the high heterogeneity in the presentation of the disease among different patients makes it difficult to make an accurate diagnosis and to apply this knowledge to effective treatments. Therefore, new studies are required to focus on translational and personalized medicine to overcome the lack of specificity and efficacy of current management. Here, we review the majority of public databases storing ‘omics’ data of pulmonary hypertension studies, from animal models to human patients. Moreover, we review some of the new molecular mechanisms involved in the pathogenesis of pulmonary hypertension, including non-coding RNAs and the application of ‘omics’ data to understand this pathology, hoping that these new approaches will provide insights to guide the way to personalized diagnosis and treatment.
  • No Thumbnail Available
    Item
    Transcatheter aortic-valve implantation. A ten years clinical experienceResultados del implante percutáneo de válvula aórtica (TAVI). Experiencia después de la primera década desde la introducción de la técnica
    (Springer, 2022) Martinez G.; Fuensalida A.; Sepulveda P.; Bulnes J.F.; Quitral J.; Pacheco F.; Valenzuela E.; Lazen R.; Flores A.; Zalaquett R.; Martinez A.; CEDEUS (Chile)
    © 2022 Sociedad Medica de Santiago. All rights reserved.Background: Transcatheter aortic-valve implantation (TAVI) was introduced in 2002 and the first implants in our country were performed in 2010. Aim: To review the TAVI experience in our hospital, considering the technology improvements and gained experience throughout this period. Material and Methods: All patients undergoing TAVI in our center were included. Results and complications were adjudicated according to the Valve Academic Research Consortium-2 (VARC-2) criteria. Patients were divided in 3 groups, according to procedural year: Period 1: 2010-2015 (n = 35); Period 2: 2016-2018 (n = 35); Period 3: 2019-2021 (n = 41). Mortality up to one year after the procedure was recorded. Results: Between 2010 and 2021, 111 TAVI procedures were performed. The mean age of patients was 82 years and 47% were women. Risk scores for in-hospital mortality were STS 6.7%, EUROSCORE II 8.0% and ACC/STS TAVR Score 4.9%. The trans-femoral route was used in 88% and a balloon-expandable valve was chosen in 82% of patients. A successful implant was achieved in 96%, with an in-hospital mortality of 1.8%. Mortality at 30 days and 1-year were 2.7 and 9.0%, respectively. During period 3, 100% of implants were successful, with no in-hospital mortality, less vascular complications (p < 0.01), less stroke (p = 0.04), less severe paravalvular leak (p = 0.01) and significantly lower rate of acute complications (p < 0.01). Conclusions: TAVI achieves excellent results. With greater experience and better available technologies, these results are even more favorable.